Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study.


Journal

Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625

Informations de publication

Date de publication:
07 2022
Historique:
received: 05 01 2021
accepted: 23 04 2021
revised: 09 04 2021
pubmed: 26 5 2021
medline: 20 7 2022
entrez: 25 5 2021
Statut: ppublish

Résumé

The blood pressure (BP) lowering response to renal denervation (RDN) remains variable with about one-third of patients not responding to ultrasound or radiofrequency RDN. Identification of predictors of the BP response to RDN is needed to optimize patient selection for this therapy. This is a post-hoc analysis of the RADIANCE-HTN SOLO study. BP response to RDN was measured by the change in daytime ambulatory systolic blood pressure (dASBP) at 2 months post procedure. Univariate regression was used initially to assess potential predictors of outcome followed by multivariate regression analysis. In the univariate analysis, predictors of response to RDN were higher baseline daytime ambulatory diastolic blood pressure (dADBP), the use of antihypertensive medications at screening, and presence of orthostatic hypertension (OHTN) whilst the presence of untreated accessory arteries was a negative predictor of response. Multivariate analysis determined that dADBP and use of antihypertensive medications were predictors of response to RDN with a trend for OHTN to predict response. Obese females also appeared to be better responders to RDN in an interaction model. RDN is more effective in patients with elevated baseline dADBP and those with OHTN, suggesting increased peripheral vascular resistance secondary to heightened sympathetic tone. These assessments are easy to perform in clinical setting and may help in phenotyping patients who will respond better to RDN.

Identifiants

pubmed: 34031548
doi: 10.1038/s41371-021-00547-y
pii: 10.1038/s41371-021-00547-y
pmc: PMC9287166
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

629-639

Informations de copyright

© 2021. The Author(s).

Références

Circulation. 2016 Sep 20;134(12):847-57
pubmed: 27576780
J Am Heart Assoc. 2017 Oct 10;6(10):
pubmed: 29018027
Circulation. 2019 Mar 17;:
pubmed: 30880441
Hypertension. 2017 Mar;69(3):494-500
pubmed: 28115517
Hypertension. 2019 Aug;74(2):349-358
pubmed: 31203727
Lancet. 2018 Jun 9;391(10137):2346-2355
pubmed: 29803589
Eur Heart J. 2015 Jan 21;36(4):219-27
pubmed: 25400162
Lancet. 2010 Dec 4;376(9756):1903-9
pubmed: 21093036
Hypertension. 2005 Apr;45(4):522-5
pubmed: 15767469
Compr Physiol. 2015 Jan;5(1):193-215
pubmed: 25589269
J Am Heart Assoc. 2018 Jun 12;7(12):
pubmed: 29895590
J Hypertens. 2018 Jul;36(7):1578-1584
pubmed: 29652730
J Hypertens. 2015 Dec;33(12):2519-25
pubmed: 26485463
Hypertension. 2007 Jan;49(1):27-33
pubmed: 17116758
Hypertension. 2010 Jul;56(1):10-6
pubmed: 20497993
J Clin Hypertens (Greenwich). 2019 Mar;21(3):426-433
pubmed: 30724451
Circulation. 1990 Sep;82(3):856-62
pubmed: 2394007
Lancet. 2018 Jun 9;391(10137):2335-2345
pubmed: 29803590
Am J Hypertens. 1997 May;10(5 Pt 1):546-51
pubmed: 9160766
J Hypertens. 2014 Dec;32(12):2422-7; discussion 2427
pubmed: 25375391
Lancet. 2017 Nov 11;390(10108):2160-2170
pubmed: 28859944
Lancet. 2020 May 2;395(10234):1444-1451
pubmed: 32234534
J Hypertens. 2016 Jan;34(1):123-9
pubmed: 26556567
JACC Cardiovasc Interv. 2019 Jun 24;12(12):1095-1105
pubmed: 31221299
Hypertension. 2014 May;63(5):984-90
pubmed: 24470464
J Cardiovasc Pharmacol. 2007 Nov;50(5):487-96
pubmed: 18030057
Eur Heart J. 2017 Jan 7;38(2):93-100
pubmed: 28158510
Hypertension. 2013 Feb;61(2):450-6
pubmed: 23283361
J Clin Hypertens (Greenwich). 2019 May;21(5):546-554
pubmed: 30900378
Eur Heart J. 2020 Apr 21;41(16):1588-1599
pubmed: 32211888
Eur J Clin Invest. 2018 Mar;48(3):
pubmed: 29355923
Lancet. 2009 Apr 11;373(9671):1275-81
pubmed: 19332353
Nat Rev Neurosci. 2006 May;7(5):335-46
pubmed: 16760914
Nat Rev Nephrol. 2013 Dec;9(12):726-38
pubmed: 24189649
Am J Hypertens. 1996 Nov;9(11):113S-120S
pubmed: 8931844

Auteurs

Manish Saxena (M)

Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, UK. m.saxena@qmul.ac.uk.

Roland E Schmieder (RE)

Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University, Erlangen, Germany.

Ajay J Kirtane (AJ)

Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA.

Felix Mahfoud (F)

Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Klinik für Innere Medizin III, Saarland University Hospital, Homburg/Saar, Germany.

Joost Daemen (J)

Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, NL, The Netherlands.

Jan Basile (J)

Seinsheimer Cardiovascular Health Program, Medical University of South Carolina, Ralph H Johnson VA Medical Center, Charleston, SC, USA.

Philipp Lurz (P)

Heart Center Leipzig, University of Leipzig, Leipzig, Germany.

Philippe Gosse (P)

Hôpital Saint-André - CHU, Bordeaux, France.

Kintur Sanghvi (K)

Deborah Heart & Lung Center, Brown Mills, NJ, USA.

Naomi D L Fisher (NDL)

The Brigham and Women's Hospital, Boston, MA, USA.

Lars C Rump (LC)

University Clinic Dusseldorf, Dusseldorf, Germany.

Atul Pathak (A)

Department of Cardiovascular Medicine, Princess Grace Hospital, Monaco, Monaco.

Peter J Blankestijn (PJ)

University Medical Center Utrecht, Utrecht, The Netherlands.

Anthony Mathur (A)

Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, UK.

Yale Wang (Y)

Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Michael A Weber (MA)

Division of Cardiovascular Medicine, State University of New York, Downstate Medical Center, New York, NY, USA.

Andrew S P Sharp (ASP)

University Hospital of Wales, Cardiff, UK.
University of Exeter, Exeter, UK.

Michael J Bloch (MJ)

Department of Medicine, University of Nevada School of Medicine, Vascular Care, Renown Institute of Heart and Vascular Health, Reno, NV, USA.

Neil C Barman (NC)

ReCor Medical, Inc, Palo Alto, CA, USA.

Lisa Claude (L)

ReCor Medical, Inc, Palo Alto, CA, USA.

Yang Song (Y)

Baim Institute for Clinical Research, Boston, MA, USA.

Michel Azizi (M)

Université de Paris, Paris, France.
Hypertension Department and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
INSERM, CIC1418, Paris, France.

Melvin D Lobo (MD)

Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH